For the quarter ending 2025-09-30, APUS has $9,250,036 in assets. $1,089,384 in debts. $6,986,617 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 6,986,617 | 8,735,323 | ||
| Prepaid expenses and other current assets | 2,099,491 | 1,614,226 | ||
| Total current assets | 9,086,108 | 10,349,549 | ||
| Property and equipment, net | 34,188 | 13,137 | ||
| Long-term portion of prepaid expenses | 129,740 | 183,995 | ||
| Total assets | 9,250,036 | 10,546,681 | ||
| Warrant liability | - | 174,413 | ||
| Accounts payable and accrued expenses | 567,633 | 119,138 | ||
| Accrued interest - related party | 21,651 | 15,351 | ||
| Advance payable to related party | 100 | 100 | ||
| Notes payable - related party | 500,000 | 500,000 | ||
| Total current liabilities | 1,089,384 | 809,002 | ||
| Long-term convertible notes payable related party | - | 0 | ||
| Total liabilities | 1,089,384 | 809,002 | ||
| Common stock, par value 0.01, 100,000,000 shares authorized 12,575,983 and 7,903,850 issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 125,760 | 125,760 | ||
| Additional paid-in capital | 17,272,661 | 17,068,433 | ||
| Accumulated deficit | -9,237,769 | -7,456,514 | ||
| Total shareholders equity (deficit) | 8,160,652 | 9,737,679 | ||
| Total liabilities and shareholders equity | 9,250,036 | 10,546,681 | ||
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)